Turoctocog alfa

Turoctocog alfa
Clinical data
Trade namesNovoEight, Esperoct
Other namesrecombinant antihemophilic factor
AHFS/Drugs.comMonograph
License data
Pregnancy
category
Routes of
administration		Intravenous (IV)
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC7480H11379N1999O2194S68
Molar mass166594.19 g·mol−1

Turoctocog alfa (trade name NovoEight) is a recombinant antihemophilic factor VIII used for the treatment of and prophylaxis of bleeding patients with haemophilia A. It is marketed by Novo Nordisk.[7][9][13] It was approved in the United States, the European Union, and Japan in 2013.[14][15][11][9]

  1. ^ "Antihemophilic factor Use During Pregnancy". Drugs.com. 20 January 2020. Archived from the original on 16 July 2020. Retrieved 11 March 2020.
  2. ^ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.
  3. ^ "Turoctocog alfa (rch)" (PDF). Archived (PDF) from the original on 16 May 2022. Retrieved 29 April 2023.
  4. ^ "Esperoct (Novo Nordisk Pharmaceuticals Pty Ltd)". Therapeutic Goods Administration (TGA). 23 June 2023. Retrieved 10 September 2023.
  5. ^ "Esperoct". Therapeutic Goods Administration (TGA). 19 June 2023. Retrieved 10 September 2023.
  6. ^ "Summary Basis of Decision (SBD) for Esperoct". Health Canada. 23 October 2014. Archived from the original on 31 May 2022. Retrieved 29 May 2022.
  7. ^ a b "NovoEight 250 IU powder and solvent for solution for injection - Summary of Product Characteristics (SmPC)". (emc). 23 December 2019. Archived from the original on 17 January 2021. Retrieved 11 March 2020.
  8. ^ "Esperoct 1000 IU powder and solvent for solution for injection - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 15 January 2021. Retrieved 2 October 2020.
  9. ^ a b c "NovoEight (- antihemophilic factor, recombinant kit". DailyMed. 30 November 2018. Archived from the original on 24 March 2021. Retrieved 11 March 2020.
  10. ^ Cite error: The named reference Esperoct FDA label was invoked but never defined (see the help page).
  11. ^ a b "NovoEight EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 30 October 2020. Retrieved 11 March 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  12. ^ Cite error: The named reference Esperoct EPAR was invoked but never defined (see the help page).
  13. ^ Spreitzer H (7 January 2014). "Neue Wirkstoffe – NovoEight". Österreichische Apothekerzeitung (in German) (1/2014): 18.
  14. ^ "Novo Nordisk annual report 2013" (PDF). Novo Nordisk. Archived (PDF) from the original on 20 November 2017. Retrieved 11 March 2020.
  15. ^ "NovoEight". U.S. Food and Drug Administration (FDA). 19 July 2017. Archived from the original on 22 July 2017. Retrieved 11 March 2020.